LEO Pharma and ICON enter a strategic partnership to propel clinical trial execution within medical dermatology
BALLERUP, DENMARK and DUBLIN, IRELAND — 10 March, 2023 — LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR)
today announced a strategic partnership that will enable LEO Pharma to
scale clinical trial execution that is patient-centric and cost
effective, and which will support the company’s overall ambition of
building one of the most effective and efficient clinical portfolio
execution organisations in the industry.
More info >> |